Peer-reviewed research from the Clayman Thyroid Center at the Hospital for Endocrine Surgery highlights a major gap in ...

Incidence and diagnosis of neuroendocrine tumors (NETs) have risen significantly over the last several decades. According to research published in JAMA Network Open in 2025, the incidence of NETs ...

Results from the OASIS 4 clinical trial show that a new drug, elinzanetant, relieved hot flashes and night sweats that can ...

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer P ...

Results from the OASIS 4 clinical trial last year showed that a new drug, elinzanetant, relieved hot flushes and night sweats that can occur because of the menopause or because of hormone treatment ...

Bireociclib plus fulvestrant significantly improved progression-free survival and response rates in advanced HR-positive ...

Patients who received exclusively traditional therapies were compared with patients who received at least one type of ...

For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, ...

Regulatory review timelines shifted from March 29 to June 29, 2026, after FDA requested more time to assess CMC/manufacturing ...

For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, ...

Good afternoon, ladies and gentlemen, and welcome to the Celcuity Fourth Quarter and Full Year 2025 Financial Call. [Operator Instructions] I would now like to turn the conference over to Jodi Sievers ...

In this segment, Dr. Gregory Vidal discusses when biomarker testing is performed during the treatment journey for ER-positive ...